Effect of Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation(TMS) on Brain Derived Neurotrophic Factor (BDNF) in Depressed Patients.
NCT ID: NCT00630123
Last Updated: 2015-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
36 participants
OBSERVATIONAL
2006-11-30
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Electroconvulsive Therapy (ECT): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.
No interventions assigned to this group
2
Transcranial Magnetic Stimulation (TMS): blood sample taken from this group at start and after therapy; subjects not randomized to therapy option.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* current depressive episode, ham-d17\>17 and ymrs\<8;
* recommended to receive ECT or TMS as part of clinical care;
* male/female;
* age 18-65;
* inpatient or outpatient;
* comorbid dysthymic disorder, gad, or social anxiety will be included;
* able to give written consent and agree.
Exclusion Criteria
* current schizophrenia, anorexia, bulimia, substance dependence (current within past 6 months excluding caffeine and nicotine);
* TMS or ECT in the last 3 months;
* any other primary diagnosis;
* uncontrolled medical illness;
* epilepsy or severe personality disorder at the discretion of the investigators;
* 3 weeks prior to first blood test, antidepressants, mood stabilizers, antipsychotics can not be added or increased;
* pregnant women or women of childbearing potential not willing to use appropriate contraception, nursing women;
* known intolerance or lack of response to treatment receiving as judged by the investigator;
* medical conditions that would affect serum levels of BDNF;
* involvement in planning and conduct of the study.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Queen's University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Roumen Milev
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roumen Milev, MD, FRCP(C)
Role: PRINCIPAL_INVESTIGATOR
Queen's University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Providence Care Mental Health Services
Kingston, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PSIY-252-06
Identifier Type: -
Identifier Source: org_study_id